Essential Partners
MYGN icon

Essential Partners’s Myriad Genetics MYGN Stock Holding History

Essential Partners’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.9K Sell
1,136
-2,798
-71% -$11.8K ﹤0.01% 1521
2026
Q2 		$22.5K Buy
3,934
+1,348
+52% +$6.12K 0.01% 856
2026
Q1 		$11.6K Sell
2,586
-4,291
-62% -$22.4K ﹤0.01% 1178
2025
Q4 		$42.3K Buy
6,877
+1,728
+34% +$12.5K 0.01% 655
2025
Q3 		$37.2K Buy
5,149
+3,979
+340% +$23.6K 0.01% 686
2025
Q2 		$6.21K Buy
+1,170
New +$6.91K ﹤0.01% 992

Other funds holding MYGN

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Harbor Capital Advisors
Harbor Capital Advisors Chicago, Illinois $1.48B AUM 30.88% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Williams & Novak
Williams & Novak Westlake Village, California $169M AUM 17.63% 1-Year Est. Return
Pinnacle Associates
Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
SignatureFD
SignatureFD Atlanta, Georgia $7.76B AUM 16.09% 1-Year Est. Return
Physician Wealth Advisors
Physician Wealth Advisors Midvale, Utah $869M AUM 17.6% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Essential Partners's MYGN Position: Q3 2026 in Review

Essential Partners reduced its Myriad Genetics (MYGN) stake by 71% in Q3 2026, selling an estimated $11.8K and leaving 1,136 shares worth $4.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1521.

Essential Partners first reported a position in MYGN in Q2 2025 and has held it in 6 quarters since. The position peaked at $42.3K in Q4 2025. 21 funds tracked by Wall St. Rank hold MYGN as of Q3 2026.

  • Essential Partners held 1,136 shares of Myriad Genetics worth $4.9K as of Q3 2026.
  • Essential Partners sold 2,798 Myriad Genetics shares in Q3 2026, an estimated $11.8K.
  • Myriad Genetics made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #1521 holding.
  • Essential Partners first reported a position in Myriad Genetics in Q2 2025 and has held it in 6 quarters since.
  • Essential Partners's Myriad Genetics position peaked at $42.3K in Q4 2025.
  • 21 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.